#USA #Dallas #RNA Therapeutics #Avidity Biosciences #MDA Conference

Avidity Biosciences Set to Present at the MDA Clinical and Scientific Conference

Avidity Biosciences, a pioneering biopharmaceutical company, continues to push the boundaries in RNA therapeutics with its innovative Antibody Oligonucleotide Conjugates (AOCs™). At the upcoming
2025 Muscular Dystrophy Association (MDA) Clinical and Scientific Conference, which will be held in Dallas, Texas from March 16-19, Avidity will present significant findings from its Phase 1/2 EXPLORE44 trial, focusing on treatments for patients with Duchenne Muscular Dystrophy (DMD).

Conference Highlights

Presentations Scheduled

Dr. Aravindhan Veerapandiyan, an Associate Professor of Pediatrics at the University of Arkansas for Medical Sciences, will be leading a key oral presentation on March 19, 2025, detailing the topline results of the EXPLORE44 trial involving del-zota. This trial focuses on demonstrating statistically significant increases in both exon skipping and dystrophin levels among patients diagnosed with DMD amenable to exon 44 skipping.

Moreover, Avidity plans to showcase two poster presentations during the conference as well. One will cover the same del-zota findings, while the second poster will discuss the Phase 3 randomized global study—HARBOR™—which assesses the efficacy and safety of another therapeutic, del-desiran, aimed at myotonic dystrophy type 1.

Networking and Insightful Discussions

On March 17, Avidity will host a breakfast forum titled "Advancing RNA Therapeutics: Exploring AOCs for Rare Neuromuscular Diseases," led by Avidity's Chief Scientific Officer, Dr. Mike Flanagan. This gathering will feature luminaries from the academic and medical fields, such as Dr. Nicholas E. Johnson, Vice Chair for Research, Department of Neurology at Virginia Commonwealth University, and Dr. Jeffrey M. Statland from the University of Kansas Medical Center, who will engage in an insightful Q&A session with conference attendees.

Investor Webcast

Further emphasizing its commitment to transparency and investor relations, Avidity management will conduct a live webcast on March 17, at 8:00 a.m. ET. This session will discuss del-zota's topline trial data in detail and will feature Dr. Kevin Flanigan, a prominent researcher in neuromuscular diseases, adding depth to the analysis.

Avidity's Mission

Avidity Biosciences is revolutionizing RNA therapeutics with its unique approach that merges the specificity of monoclonal antibodies with the precision of oligonucleotide therapies. This mission aims to target and treat diseases that have long remained beyond the reach of current RNA therapies. With its proprietary AOC platform, the company has achieved groundbreaking success in delivering RNA directly to muscle tissues, making substantial strides for conditions like DMD, myotonic dystrophy, and facioscapulohumeral muscular dystrophy (FSHD).

As Avidity continues to expand its clinical development programs and pipelines, its plans include branching into cardiology and immunology through collaboration with key partners. Headquartered in San Diego, California, Avidity remains at the forefront of this essential field, working diligently to ensure that the promise of novel RNA therapeutics becomes a reality for patients in need.

For those interested in learning more about Avidity Biosciences and its cutting-edge developments in RNA therapeutics, additional information and the published materials from the conference can be accessed through their official website post-event.

Conclusion

The upcoming presentations and events at the MDA 2025 Conference will not only showcase Avidity’s innovative research but also create valuable opportunities for collaboration and discussion among thought leaders in the field. As the spotlight shines on Avidity, the burgeoning potential of RNA therapeutics offers hope to patients affected by rare neuromuscular diseases.